| 摘要 |
Crystalline form, Form N-2, of N, Ndicyclopropyl-4-(l,5-dimethyl-1 Hpyrazol-3-ylamino)-6-ethyl-l-methyl-l,6-dihydroimidazo[4,5- d]pyrrolo[2,3-b]pyridine-7-carboxamide (Compound I) is provided. Also provided are a pharmaceutical composition and an oral dosage form comprising Form N-2 of Compound I as well as a method of using the Form N-2 of Compound I in the treatment of myeloproliferative disorders, which include polycythaemia vera, thrombocythaemia and primary myelofibrosis. |
